Nitrocine (Glyceryl Trinitrate)

Glyceryl trinitrate is converted to nitric oxide inside vascular smooth‑muscle cells. Nitric oxide activates soluble guanylate cyclase, increasing cGMP levels, which cause smooth‑muscle relaxation and dilation of veins and arteries. This vasodilation decreases preload and afterload, improving myocardial oxygen supply and lowering systemic blood pressure.

The specific dose and infusion rate of Nitrocine are determined by the prescribing clinician based on the patient’s condition, response, and monitoring parameters. Healthcare professionals adjust the regimen to achieve the desired haemodynamic effect while avoiding excessive hypotension.

Safety data for Glyceryl trinitrate in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To request Nitrocine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nitrocine belongs to the organic nitrate class, providing rapid, short‑acting vasodilation. Compared with oral nitrates, it offers immediate onset suitable for emergency settings. Unlike beta‑blockers or calcium‑channel blockers, its primary effect is venous dilation, which reduces cardiac preload more directly, but it may require careful blood‑pressure monitoring.

Nitrocine should be stored below 25 °C in its original container, protected from moisture and light because the solution is light‑sensitive. Keep the vial sealed when not in use and avoid exposure to high temperatures or direct sunlight to maintain potency.

Nitrocine is administered intravenously, typically as a continuous infusion or intermittent bolus under strict clinical supervision. The infusion set should be primed with the solution, and the rate is adjusted according to the patient’s blood‑pressure response and therapeutic goals.

The most serious risks include severe hypotension, myocardial ischemia due to coronary steal, methemoglobinemia, and life‑threatening allergic reactions. Continuous haemodynamic monitoring is essential, and any signs of profound blood‑pressure drop or chest pain should prompt immediate medical intervention.

Nitrocine is contraindicated in patients with known hypersensitivity to organic nitrates, those who have taken phosphodiesterase‑5 inhibitors within the previous 24 hours, and individuals with severe anaemia, increased intracranial pressure, or uncompensated shock where further vasodilation could be harmful.